Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer
Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center, shared a recent article by Jacob B Reibel on LinkedIn:
“Drug shortages disrupt clinical care in an already struggling health care system and need to be addressed and not by saying they have no impact.
Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer.”
Title: Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer
Authors: Jacob B Reibel, Lova L Sun, Ravi B Parikh, Nadim Mahmud, Lainie P Martin, Rebecca A Hubbard and Ronac Mamtani
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
More posts featuring Wafik S. El-Deiry.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023